Skip to content

Impact of ATOrvastatin REload on the Prevention of Contrast-INduced Nephropathy in patients on Chronic Statin Therapy: A prospective randomized trial (ATORE-CIN)

Impact of Atorvastatin Reload on the Prevention of Contrast-Induced Nephropathy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
PACTR
Registry ID
PACTR202110707328144
Enrollment
102
Registered
2021-10-25
Start date
2020-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal diseases

Interventions

Reload patients on chronic statin therapy with high dose of atorvastatin
no relaod statin

Sponsors

hedi chaker hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: This is a prospective, randomized, single-blind, controlled trial, implemented in all consecutive patients (older than 18 years), undergoing coronary angiography or percutaneous coronary intervention in our department between June 2020 and September 2020 and who had already been receiving atorvastatin for at least one week, before admission.

Exclusion criteria

Exclusion criteria: *patients admitted because of an acute coronary syndrome in whom a loading dose is recommended according to guidelines, *statin-naïve patients, *patients who received a statin other than atorvastatin before the procedure, *patients already receiving 80 mg atorvastatin, patients requiring dialysis and those with eGFR less than 15 ml/min/ 1.73 m2, *patients who were exposed to a contrast medium within 7 days, patients with an allergy to contrast media, *patients with cardiogenic shock or severe cardiac insufficiency (left ventricular ejection fraction LVEF <20%), *patients with severe liver damage, malignant tumor, infectious disease, or fever, *and those who refused to consent. * patients who didn't return to get control laboratory tests

Design outcomes

Primary

MeasureTime frame
the incidence of Cys-based CIN defined as an increase in serum CyC concentration by 10% above the baseline value 24 hours after contrast media administration (17) and the incidence of SCr-based CIN defined as the increase in SCr the concentration of 44.2 mmol/L or 25% above baseline within 72 hours after exposure to contrast media.

Secondary

MeasureTime frame
The secondary end-point was to detect any acute kidney injury by a significant rise in cystatin C level between baseline and 24 hours in the two groups ( AR and NR groups). We assessed the risk of CIN before the procedure using the Mehran score (20). The risk of CIN was considered low if Mehran’s score =0-5, moderate if Mehran’s score=6-10, High if Mehran’s score>10.

Countries

Tunisia

Contacts

Public Contactrania hammami

professor

raniahammami@yahoo.fr0021624056985

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026